Global Kinetics adds former EMA head to board
Global Kinetics Corporation has appointed former EMA chief Dr Thomas Lönngren to its board, as it seeks to commercialise its Parkinson’s KinetiGraph (PKG) technology.
Lönngren is a Swedish regulatory affairs veteran with a background in health systems, drug and medical device regulations.
Global Kinetics has made the appointment as part of its EU expansion strategy for PKG, a device for monitoring Parkinson’s symptoms and helping to optimise treatment options.
The company also revealed it has been awarded a key European patent covering its intellectual property. The patent covers the company’s ability to record, measure and assess clinical movement data using the PKG technology, and the mathematical algorithms associated with the data analysis.
Global Kinetics CEO Andrew Maxwell said the two developments will be key to the company’s long-term plans for the device.
“Dr Lönngren has an impeccable background in health systems, drug, medical device regulations and in working with international government and industry stakeholders at the highest levels,” he said.
“We expect his expertise to prove invaluable as we deliver value for people with Parkinson’s disease, clinicians, governments and commercial stakeholders worldwide.”
The PKG already has clearance from the FDA, EMA and TGA.
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
High folic acid in pregnancy could cause early bleeding
Women taking at least 800 micrograms of folic acid daily were more likely to report spotting and...
Genetics shape our personality and life outcomes more than we thought
Scientists have identified >1200 genetic variants associated with personality traits,...
